BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.1%

Neg 0% Neu 87.1% Pos 0%

BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.

Comments

No comments yet. Be the first!